Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2021 08:30 ET | Source: Evaxion Biotech

Evaxion Biotech Appoints Lars Holtug to the Board of Directors

COPENHAGEN, Denmark, May 26, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
May 13, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Q1 2021 Financial Results and Provides Business Update

Raised net proceeds of $27.9 million in U.S. initial public offering in February 2021Lead programs EVX-01 and EVX-02 on track for Phase 1/2a data readouts late in Q2Product candidates EVX-03 and...
May 06, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech to Host Q1 2021 Corporate Update Conference Call & Webcast on May 13

COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
April 20, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Presents Paper on Potential of Deep Data on Immune Complex Stability to Optimize Cancer Immunotherapy

COPENHAGEN, Denmark, April 20, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
April 06, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update

Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 millionClinical development on track with dosing of first patient in Phase 1/2a melanoma...
March 30, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech to Host Full-Year 2020 Corporate Update Conference Call & Webcast on April 6

COPENHAGEN, Denmark, March 30, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
March 16, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Publication of Study on S. aureus Bacterium in Scientific Reports

COPENHAGEN, Denmark, March 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
February 16, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Opens New Office and Laboratories to Support Future Growth

COPENHAGEN, Denmark, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to...
February 10, 2021 07:30 ET | Source: Evaxion Biotech

Evaxion Biotech Closes its U.S. Initial Public Offering of American Depositary Shares

COPENHAGEN, Denmark, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of...
February 04, 2021 16:16 ET | Source: Evaxion Biotech

Evaxion Biotech Announces Pricing of Initial Public Offering

COPENHAGEN, Denmark, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (“Evaxion”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve...